Takafumi Iwatsubo
Overview
Explore the profile of Takafumi Iwatsubo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwatsubo T
Drug Metab Pharmacokinet
. 2019 Nov;
35(1):71-75.
PMID: 31757749
The U.S. Drugs and Food Administration (FDA) and the Ministry of Health, Labor and Welfare of Japan (MHLW) issued the drastically revised draft guidance and final guideline on drug-drug interactions...
2.
Ohtsu Y, Sonoda T, Susaki Y, Tohda T, Fukunaga Y, Iwatsubo T, et al.
Biopharm Drug Dispos
. 2014 Oct;
36(1):34-48.
PMID: 25277346
The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). After a single oral administration to rats, ASP3258 is...
3.
Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, et al.
Mol Pharm
. 2013 Apr;
10(5):1783-94.
PMID: 23560393
Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely...
4.
Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, et al.
Xenobiotica
. 2012 Nov;
43(6):534-47.
PMID: 23167531
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated after a single oral administration of [(14)C]darexaban maleate at a dose of...
5.
Nagasaka Y, Oda K, Iwatsubo T, Kawamura A, Usui T
Biopharm Drug Dispos
. 2012 Aug;
33(6):304-15.
PMID: 22847220
The inhibition potencies of aripiprazole and its active metabolite, dehydroaripiprazole, on the activities of human multidrug resistance protein 1 (MDR1/ABCB1; P-glycoprotein), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein...
6.
Takusagawa S, Miyashita A, Iwatsubo T, Usui T
Xenobiotica
. 2012 Jul;
42(12):1187-96.
PMID: 22834478
The potential for mirabegron, a β(3)-adrenoceptor agonist for the treatment of overactive bladder, to cause drug-drug interactions via inhibition or induction of cytochrome P450 (CYP) enzymes was investigated in vitro....
7.
Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T
Xenobiotica
. 2012 Apr;
42(10):957-67.
PMID: 22509825
1. Human cytochrome P450 (CYP) enzymes and esterases involved in the metabolism of mirabegron, a potent and selective human β(3)-adrenoceptor agonist intended for the treatment of overactive bladder, were identified...
8.
Sato Y, Miyashita A, Iwatsubo T, Usui T
Drug Metab Dispos
. 2012 Apr;
40(7):1389-96.
PMID: 22504157
The aims of this study were to develop a robust method for simultaneous quantification of carboxylesterases (CESs) 1 and 2 and to quantify those absolute protein levels in human liver...
9.
Shiraga T, Yajima K, Teragaki T, Suzuki K, Hashimoto T, Iwatsubo T, et al.
Biol Pharm Bull
. 2012 Mar;
35(3):413-21.
PMID: 22382330
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma after oral administration of darexaban to humans and is the pharmacologically...
10.
Sato Y, Miyashita A, Iwatsubo T, Usui T
Drug Metab Dispos
. 2012 Feb;
40(5):902-6.
PMID: 22293119
The aim of this study was to conclusively determine the enzyme responsible for the hydrolysis of oxybutynin in human liver. Hydrolysis in human liver microsomes (HLMs) and human liver cytosol...